Pharmaceutical - Genito-urinary

Filter

Current filters:

Genito-urinary

Popular Filters

1 to 25 of 33 results

India’s IPAB upholds Pfizer’s Detrol patent

India’s IPAB upholds Pfizer’s Detrol patent

27-03-2014

In a positive development for US drug giant Pfizer, India's Intellectual Property Appellate Board (IPAB)…

Asia-PacificDetrolGenito-urinaryIndiaPatentsPfizerPharmaceuticalRanbaxy Laboratories

Positive top-line Ph III results with ceftolozane/tazobactam in cUTI

25-11-2013

US biopharma company Cubist Pharmaceuticals has revealed positive top-line results from its pivotal Phase…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsGenito-urinaryPharmaceuticalResearchtazobactam

SOBI gains rights to distribute Ravicti in Middle East

01-10-2013

Swedish Orphan Biovitrum says Hyperion Therapeutics has granted it exclusive rights to distribute its…

Genito-urinaryHyperion TherapeuticsLicensingPharmaceuticalRavictiRest of the WorldSobiSwedish Orphan Biovitrum

UK MHRA licenses Allergan's Botox for use in patients with overactive bladder

11-09-2013

Botox (botulinum toxin type A), from US drugmaker Allergan (NYSE: AGN), has been licensed by the UK Medicines…

AllerganBotoxEuropeGenito-urinaryPharmaceuticalRegulation

Netherlands first to approve Astellas' Vesomni

23-05-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines…

Astellas PharmaEuropeGenito-urinaryPharmaceuticalRegulationVesomni

Drais Pharma to develop third Astellas compound through Tacurion

08-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Auxilium Pharma acquires Actient in $585 million deal

29-04-2013

Specialty drugmaker Auxilium Pharmaceuticals (Nasdaq: AUXL) says that it has completed the acquisition…

Actient PharmaAuxilium PharmaceuticalsGenito-urinaryMen's HealthMergers & AcquisitionsPharmaceutical

Positive data expected for RedHill Biopharma's Crohn's disease candidate

22-04-2013

Analysts at Roth Capital Partners have launched coverage of Israel-based specialty pharma company RedHill…

FinancialGenito-urinaryPharmaceuticalRBH-104RedHill BiopharmaResearch

Lilly's ED drug Cialis meets endpoint in LUTS/BPH study

19-03-2013

US drug major Eli Lilly (NYSE: LLY) presented results yester day at the annual European Association of…

CialisEli LillyGenito-urinaryMen's HealthPharmaceuticalResearch

Dainippon Sumitomo partners with Nippon Shinyaku for urology drug AMP-986

12-03-2013

Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded…

AMP-986Asia-PacificDainippon Sumitomo PharmaGenito-urinaryLicensingNippon ShinyakuPharmaceutical

Research results for Pfizer's Chantix, Pristiq and Toviaz

27-01-2013

Global drugs behemoth Pfizer (NYSE: PFE) last week released a batch of new clinical trial data relating…

ChantixGenito-urinaryNeurologicalPfizerPharmaceuticalPristiqResearchToviaz

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine

21-01-2013

US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Astellas' Betmiga Oked in EU for overactive bladder

14-01-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has received approval from…

Astellas PharmaBetmigaEuropeGenito-urinarymirabegronPharmaceuticalRegulation

Astellas links with KEK on tropical diseases; Upgraded by CS analysts

25-09-2012

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with the High Energy…

Astellas PharmaFinancialGenito-urinaryMyrbetriqOncologyPharmaceuticalResearchTropical diseasesXtandi

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close

07-08-2012

The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

Positive Ph IV data for Pfizer and UCB's Toviaz

06-08-2012

Global drugs behemoth Pfizer (NYSE: PFE) has released positive Phase IV study results assessing the efficacy…

Genito-urinaryPfizerPharmaceuticalResearchToviazUCB

FDA approves Astellas' Myrbetriq for overactive bladder

02-07-2012

The US Food and Drug Administration has approved Japanese drug major Astellas Pharma's (TYO: 4503) Myrbetriq…

Astellas PharmaGenito-urinarymirabegronMyrbetriqNorth AmericaPharmaceuticalRegulation

Kyowa Hakko debuts Poteligeo in Japan; co-promotes Minirinmelt with Ferring

29-05-2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has launched Poteligeo (mogamulizumab)…

Asia-PacificFerring PharmaceuticalsGenito-urinaryKyowa Hakko KirinMarkets & MarketingMinirinmeltOncologyPharmaceuticalPoteligeo

1 to 25 of 33 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top